Seattle Genetics Hires Waller To Lead Regulatory Affairs, as SGN-35 Heads to Pivotal Trial

Seattle Genetics, the developer of targeted cancer drugs, said today it has hired Elaine Waller as senior vice president in charge of regulatory affairs. The Bothell, WA-based company (NASDAQ: SGEN) has some big meetings on the docket with U.S. regulators this fall, as it prepares its plan for a pivotal clinical trial of SGN-35 for Hodgkin’s disease. Waller has 20 years’ experience in regulatory affairs, most recently with Bothell, WA-based Sonus Pharmaceuticals.